Seal Medical Completes Series A+ Financing Led by Sequoia China to Accelerate Expansion in Digital Dentistry

VCBeat has learned that Changzhou Sailuo Medical Technology Co., Ltd. recently completed its Series A+ financing round, led by HongShan, with participation from HAOYUE CAPITAL, Chang Gaoxin, and He Capital. The financing amount exceeded RMB 100 million.This new round of financing, completed by Selle Medical shortly after its Series A funding in July, saw continued increased holdings from existing shareholders HongShan and HAOYUE CAPITAL, demonstrating strong confidence from the investment community in Selle Medical.

Full Product Lineup of 8 Teeth, the Dental Brand Under Sail Medical

Changzhou Sailuo Medical Technology Co., Ltd., established in 2016, is a specialized manufacturer of dental medical equipment and consumables. The company’s founding team hails from global dental industry giants and leading domestic healthcare enterprises. Leveraging its accumulated R&D strengths from the outset, the company successfully integrated its mature research and development system into the dental sector.

At its inception, Sailuo Medical entered the market by providing root canal treatment equipment considered “essential for clinic opening” to dental practices. By leveraging domestic and international social media operations, it built a high-value private traffic pool, precisely targeting dentists. Through the application of consumer goods and internet-centric mindsets, it achieved differentiation from traditional medical enterprises.

Within just five years, Sailuo Medical has rapidly established high-quality sales channels in 130 countries and regions worldwide, achieving a compound annual growth rate (CAGR) of 190% over the past three years. Despite the global impact of the pandemic in 2020, Sailuo Medical achieved counter-trend growth, with its sales revenue successfully surpassing the RMB 100 million mark. After completing the closed-loop ecosystem for root canal treatment, Sailuo Medical gradually expanded its business boundaries by launching imaging equipment and dental consumables. These products quickly garnered positive market reception, further enhancing brand influence and strengthening its sales channels.

This round of fundraising will further bolster SaiLe Medical’s deepening presence in the field of basic dental equipment, while also accelerating its strategic layout around dental digitalization and high-value consumables. Looking at the global dental digitalization market, European and American dental enterprises have, through years of technological accumulation and capital integration, largely interconnected their product offerings across all stages of the digital workflow. Digitalization has thus evolved into an ecosystem, fully demonstrating its advantages in high efficiency and low cost.

However, for most enterprises in China and in less developed countries and regions, digital products remain confined to individual segments, with barriers between digital processes yet to be broken. Saile Medical is confident in leveraging its existing platform advantages, integrating industrial resources in the digital sector with the support of top-tier capital, gradually refining its product pipeline, and building an ecosystem-oriented one-stop platform to play a more significant role in the global dental healthcare industry chain.

Mr. Tao Huan, Founder of Sailuo Medicalexpressed deep gratitude to all investors for their trust in Sailuo Medical. In recent years, Chinese dental companies have rapidly elevated their global standing, with product quality, service standards, and brand image increasingly gaining market recognition. Sailuo Medical is honored to have emerged amidst this trend as a dental company with a global perspective. Over the past few years, the company has leveraged its technological and marketing advantages to rapidly establish a worldwide sales network. Looking ahead, it aims to harness the power of capital to integrate more resources and expand into broader areas within the dental sector, striving to become a global provider of comprehensive dental solutions.

Mr. Lu Xiaobo, Partner at HongShanHongShan expressed its pleasure in leading the new round of financing for Selle Medical. The dental industry is a key sector of focus for HongShan. Selle Medical demonstrates significant innovation advantages and high cost-effectiveness in its products. By entering the market with essential, high-frequency equipment for clinical practice, it provides high-quality, compact devices that closely meet clinical needs, resulting in strong customer satisfaction and user stickiness. The company has successfully expanded from endodontic treatment products into related fields such as dental imaging. Within just a few years, it has emerged as a leading Chinese dental company in global expansion. HongShan looks forward to Selle Medical’s continued rapid growth and business boundary expansion, further enriching its product portfolio and solutions for the comprehensive general dentistry closed-loop ecosystem, while supplementing its offerings in the high-value dental consumables segment, ultimately building itself into a global one-stop dental solutions provider.

Mr. Yang Zhenjun, Partner at HAOYUE CAPITALIt was stated that over the past five years, Sailuo Medical has grown into a leading global platform for dental medical devices in China, with its domestic and international market shares continuing to rise. Its product portfolio has expanded from essential equipment required for clinic establishment to high-end imaging and optical devices, offering an extremely diverse range of categories. The company’s products demonstrate clear advantages in quality and functional innovation, earning recognition from customers worldwide.

Meanwhile, the company is actively laying out digital products and solutions as well as related high-value consumables, creating a closed loop around surgical procedures. This strategy is expected to enable rapid business expansion by leveraging its strong global channel foundation. HAOYUE CAPITAL remains bullish on the development prospects of Saile Medical, firmly believing that China can produce a dental healthcare platform enterprise comparable to international giants, one that will play a more significant role in the global dental healthcare industry chain and benefit more patients and physicians worldwide.

Mr. Feng Xiaoyu, Chairman of Changzhou Gaoxin Jinlong HoldingsIt was stated that Sailuo Medical is an outstanding medical device enterprise in our Changzhou High-Tech Zone. As the industrial fund of the High-Tech Zone, we are pleased to join leading institutions such as HongShan and HAOYUE CAPITAL in investing in Sailuo to support its development. The High-Tech Zone has clearly identified the “Two Specialties and Three New” industries as key areas for future industrial development and is actively making strategic investments, with “New Medicine and Medical Devices” being a crucial sector within the “Three New.” We hope Sailuo will continue to thrive, develop globally best-selling dental medical products, consistently innovate new categories and products in dental care, and ultimately become a platform company providing comprehensive solutions in the dental field.

Sequoia Capital has always been committed to helping entrepreneurs build enduring, great companies by providing its portfolio companies with abundant global resources and valuable historical expertise. Over the past 49 years, Sequoia Capital has invested in numerous innovative enterprises and leaders shaping industry trends. As “entrepreneurs behind entrepreneurs,” HongShan (Sequoia China) focuses on investment opportunities in three key sectors: TMT, healthcare, and consumer goods/services. Over the past 16 years, HongShan has invested in nearly 600 companies characterized by distinct technological advantages, innovative business models, and high growth potential.

HAOYUE CAPITAL, established in January 2014, is committed to serving as a bridge connecting China’s healthcare sector with capital markets. Its research and transaction coverage spans multiple sub-sectors, including innovative medical devices, biopharmaceuticals, in vitro diagnostics (IVD) and precision medicine, healthcare services, and smart healthcare. The firm’s team comprises seasoned investment bankers with extensive experience in China’s healthcare industry. By closely monitoring market dynamics and investment trends in the healthcare sector over the long term, HAOYUE CAPITAL publishes weekly investment updates and special thematic research reports, offering its perspectives on new policies and emerging frontiers.

Changzhou Hejia Capital Management Co., Ltd. (hereinafter referred to as “Hejia Capital”) was established in December 2015 with a registered capital of RMB 300 million, serving as the fund manager for the Industrial Guidance Fund of Changzhou High-Tech Zone (Xinbei District). Currently, it manages Phase I of the industrial fund, namely Changzhou Tianrong Equity Investment Center (Limited Partnership), with a total scale of RMB 2.5 billion, and Phase II of the industrial fund, namely Changzhou Xinbei District Phase I Sci-Tech Innovation Investment Center (Limited Partnership), with a total scale of RMB 1 billion. By managing and operating these industrial funds, Hejia Capital facilitates the transformation and upgrading of key industries under the “Two Specialties and Three New Industries” framework in Changzhou High-Tech Zone, promotes the high-quality development of regional key enterprises such as Trina Solar, Welle Environmental Engineering, and Jiangsu Huanya Medical Technology Group, and actively introduces major projects like Antai Composite Materials. Additionally, through the model of reinvesting in subsidiary funds, the company has established capital ties with Shenzhen Capital Group and Antai Technology, further amplifying its financial leverage. In 2019, the company was recognized as a “Leading Brand Enterprise in Venture Capital in Jiangsu Province” and was honored as an “Excellent Venture Capital Team in Jiangsu Province” for two consecutive years.